|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Name of trial**  | **Outline of trial**  | **Eligible CLL/SCL population**  | **Centres open**  | **Treatment**  | **Website for more information**  | **Email**  |
| **BGB-11417-101**  | BCL2 Inhibitor BGB-11417 (Sonrotoclax); w or wo Zanubrutinib  | Treatment naïve; or relapse/refractory; needing treatment  | Wellington; North Shore; ADHB  | A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Sonrotoclax  and Zanubrutinib  | <https://clinicaltrials.gov/study/NCT04277637>   | clinicaltrials@beigene.com  |
| **LOXO-BTK-20030**  | Pirtobrutinib (LOXO-305) versus Ibrutinib  | All patients needing treatment   | Dunedin  | A Phase 3, Randomised Study   | <https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=20969&isClinicalTrial=True>  | info@anzctr.org.au  |
| **AbbVie M14-728**  | Venetoclax for Relapsed/refractory CLL/SLL in !7p deletion  | Relapsed/refractory CLL/SLL in 17p deletion  | Christchurch  | Participants with 17p deletion status will receive various doses of Venetoclax once daily   | <https://clinicaltrials.gov/study/NCT02966756>  | abbvieclinicaltrials@abbvie.com  |
| **Bellwave 01**  | Nemtabrutinib Versus Investigator’s Choice of Ibrutinib or Acalabrutinib  | Treatment naïve Needing treatment    | North Shore Middlemore Waikato  | A Phase 3, Randomised Study   |    |    |